Unlock stock picks and a broker-level newsfeed that powers Wall Street. Upgrade Now LSE - Delayed Quote • CAD Aptose Biosciences Inc. (0UI8.L) Follow Add holdings 5.16 +3.83 +(287.97%) As of March 24 at 5:03:23 PM GMT. Market Open. Comparisons Indicators Technicals Corporate Events Draw List View Grid View Detach Attach No Tool Measure UNDO Redo All All Favorites Text Statistics Technicals Fibonacci Markings Lines Annotation Arrow Line Horizontal Vertical Rectangle Trend Line Measurement Line Average Line Callout Channel Check Continuous Crossline Elliott Wave Ellipse Doodle Fib Projection Fib Arc Fib Fan Fib Time Zone Focus Gann Fan Gartley Heart Pitchfork Quadrant Lines Ray Regression Line Fib Retracement Star Speed Resistance Arc Speed Resistance Line Time Cycle Tirone Levels Volume Profile Cross Magnet Clear All Drawings Restore Default Parameters Loading Chart for 0UI8.L 1D 5D 1M 3M 6M YTD 1Y 5Y All Date Range 1 min Recent News: 0UI8.L View More All News Press Releases SEC Filings Aptose Announces Auditor Not Standing for Re-Appointment Aptose to Present at the 2025 Bloom Burton & Co. Healthcare Investor Conference Aptose Biosciences shares to delist from Nasdaq as of April 2 Aptose Common Shares to Delist from Nasdaq as of April 2, 2025 Aptose Biosciences price target raised to $6 from $2 at H.C. Wainwright Aptose Reports Year End 2024 Results and Corporate Highlights Aptose Biosciences Meets Nasdaq Minimum Bid Price Compliance Aptose Announces Positive Clinical Safety Review Committee (CSRC) Approval to Dose Escalate in Phase 1/2 Tuscany Trial of Frontline Triple Drug Therapy with Tuspetinib Amid Complete Responses and Favorable Safety in First Cohort Aptose Announces Reverse Share Split Aptose Enters into $25 Million Committed Equity Facility and Establishes New At-The-Market Facility Aptose’s Frontline Triple Drug Therapy with Tuspetinib Achieves Notable Responses in Newly Diagnosed AML Patients in the Phase 1/2 TUSCANY Trial